| Withdrawn | Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma NCT02082405 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple M NCT02224729 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Terminated | Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myel NCT01954784 | Case Comprehensive Cancer Center | Phase 1 |
| Withdrawn | Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell NCT01812720 | Mayo Clinic | Phase 2 |
| Completed | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Mye NCT01849783 | Margarida Magalhaes-Silverman | Phase 2 |
| Active Not Recruiting | Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With N NCT01816971 | University of Chicago | Phase 2 |
| Terminated | Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy NCT01676961 | NYU Langone Health | Phase 2 |
| Completed | Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant NCT01706666 | Mayo Clinic | Phase 2 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients NCT01653106 | Ohio State University Comprehensive Cancer Center | N/A |
| Terminated | High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Tr NCT01534143 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Terminated | Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple M NCT01518465 | University of Southern California | Phase 2 |
| Completed | Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple NCT02037256 | Barbara Ann Karmanos Cancer Institute | N/A |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921 | Martin, Paul | N/A |
| Terminated | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067 | City of Hope Medical Center | Phase 2 |
| Terminated | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Bloo NCT01076270 | Fred Hutchinson Cancer Center | N/A |
| Completed | Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myel NCT01074060 | City of Hope Medical Center | Phase 1 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Completed | Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active NCT01057225 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Und NCT00998049 | Mayo Clinic | Phase 2 |
| Completed | Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma NCT00693433 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Pat NCT00849251 | University of Washington | Phase 1 / Phase 2 |
| Completed | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors NCT00799461 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 3 |
| Terminated | Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT00719901 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Trans NCT00619684 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Sunitinib in Treating Patients With Relapsed Multiple Myeloma NCT00514137 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previousl NCT00522392 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Terminated | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma NCT00112723 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT00310024 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous St NCT00112827 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT00079456 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma NCT00075881 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated W NCT00182663 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer NCT00060372 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT00047203 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Pat NCT00006244 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |
| Completed | Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Pa NCT00003954 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation NCT00002787 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 1 |
| Completed | Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Trea NCT00002556 | National Cancer Institute (NCI) | Phase 3 |
| Withdrawn | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma NCT00112879 | The Cleveland Clinic | Phase 2 |